
Peripheral nerve injuries - Pipeline Insight, 2024
Description
Peripheral nerve injuries - Pipeline Insight, 2024
DelveInsight’s, “Peripheral nerve injuries - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Peripheral nerve injuries pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Peripheral nerve injuries: Overview
Peripheral nerve injuries (PNI) include a variety of conditions in which one or more peripheral nerves are damaged. It leads to neurological deficits distal to the level of the lesion present. PNIs affect all age groups and damage to the peripheral nerves is known as peripheral neuropathy. The symptoms of PNI may vary depending on the nerve fiber affected and include pain in the affected area, burning sensations and numbness. The diagnosis of PNI involves a medical history, neurological examination, and, in some cases, diagnostic tests like x-ray if fracture is suspected, CT/MRI, or electrodiagnostic examination. Treatment for PNI depends on the injury and other external factors including early nerve exploration and repair. Nonsurgical treatments include medications, immobilization and physical therapy. Surgical treatment may be needed if the individual has persistent neurologic symptoms.
""Peripheral nerve injuries - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral nerve injuries pipeline landscape is provided which includes the disease overview and Peripheral nerve injuries treatment guidelines. The assessment part of the report embraces, in depth Peripheral nerve injuries commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral nerve injuries collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral nerve injuries R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral nerve injuries.
This segment of the Peripheral nerve injuries report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Peripheral nerve injuries Emerging Drugs
- NTX-001: Neuraptive Therapeutics
- ONO-2910: Ono Pharmaceutical
Further product details are provided in the report……..
Peripheral nerve injuries: Therapeutic Assessment
This segment of the report provides insights about the different Peripheral nerve injuries drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Peripheral nerve injuries
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Peripheral nerve injuries: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Peripheral nerve injuries therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral nerve injuries drugs.
Peripheral nerve injuries Report Insights
- Peripheral nerve injuries Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Peripheral nerve injuries drugs?
- How many Peripheral nerve injuries drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral nerve injuries?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral nerve injuries therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Peripheral nerve injuries and their status?
- What are the key designations that have been granted to the emerging drugs?
- Neuraptive Therapeutics
- MicroCures
- SanBio
- KannaLife Sciences
- Sonnet BioTherapeutics
- Ono Pharmaceutical
- AxoGen
- MedGenesis Therapeutix
- Tetragenetics
- NTX-001
- siFi2
- SB 308
- KLS-13019
- Recombinant IL-6
- ONO-2910
- Avance Nerve Graft
- SON-081
- Liatermin
- TTG-108
Table of Contents
50 Pages
- Introduction
- Executive Summary
- Peripheral nerve injuries: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Peripheral nerve injuries – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- NTX-001: Neuraptive Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Recombinant Interleukin-6: Sonnet Biotherapeutics Holdings
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical/Discovery Stage Products
- Comparative Analysis
- Liatermin: MedGenesis Therapeutix
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Peripheral nerve injuries Key Companies
- Peripheral nerve injuries Key Products
- Peripheral nerve injuries- Unmet Needs
- Peripheral nerve injuries- Market Drivers and Barriers
- Peripheral nerve injuries- Future Perspectives and Conclusion
- Peripheral nerve injuries Analyst Views
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.